Ery­tech shares soar on pos­i­tive re­sults for PhI­Ib pan­cre­at­ic can­cer tri­al; Ar­Qule’s tivan­ti­nib fails yet again in PhI­II can­cer study

→ France’s Ery­tech Phar­ma says it gar­nered pos­i­tive da­ta in a Phase IIb study of eryas­pase com­bined with chemo for sec­ond-line metasta­t­ic pan­cre­at­ic can­cer, send­ing shares $ERYP rock­et­ing up 75%. The drug hits its co-pri­ma­ry end­points with sig­nif­i­cant im­prove­ments for pro­gres­sion-free sur­vival as well as over­all sur­vival. Pas­cal Ham­mel, prin­ci­pal in­ves­ti­ga­tor of the study, com­ment­ed: “These re­sults gen­er­at­ed by eryas­pase in com­bi­na­tion with the stan­dard of care are high­ly en­cour­ag­ing and com­pare fa­vor­ably to gem­c­itabine or FOL­FOX treat­ment ad­min­is­tered alone. The re­sults of this study sup­port eryas­pase as a po­ten­tial treat­ment op­tion for pa­tients with metasta­t­ic pan­cre­at­ic can­cer in the sec­ond-line set­ting.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER